TQB2450 with anlotinib shows promise in STS

TQB2450 combined with anlotinib showed promising activity in patients with alveolar soft part sarcoma (ASPS), according to results from a phase 2 study. In this single-arm study, 30 patients with locally advanced or metastatic soft tissue sarcoma (LA/M STS) previously unresponsive to ≥1chemotherapy regimen were administered anlotinib orally from day...